Insurance Companies Make It Difficult for Kids with Asthma to Get Biologics - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Insurance Barriers Limit Children’s Access to Biologics for Asthma

  • By

  • Debbie Bunch

  • November 16, 2026

Share

  • 1

    The study examined 326 biologic prescriptions issued by allergists to pediatric patients from 2018 through 2026.

  • 2

    The children had a mean age of 11 years, and approximately half were male.

  • 3

    Omalizumab accounted for 55.8% of prescriptions, and dupilumab accounted for 26%.

  • 4

    Insurance approval was required for nearly all prescriptions, and approximately 4 in 10 were ultimately denied.

  • 5

    Denials commonly involved step-therapy requirements or failure to meet insurer criteria, and treatment initiation generally took more than 1 month.

Original Source(s)

Related Content